Mycamine (Micafungin Sodium)

Micafungin sodium inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. This weakens the wall, leading to osmotic instability and cell lysis while sparing human cells.

The dosage of Mycamine is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and treatment setting. Healthcare professionals should follow local guidelines and product labeling when prescribing.

Safety data for micafungin sodium in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Mycamine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mycamine belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins such as micafungin have a favorable safety profile and are effective against many Candida species, including some azole‑resistant strains, making them a valuable alternative in invasive infections.

Mycamine should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Mycamine is supplied as an intravenous solution and is administered by slow IV infusion over a period recommended by the prescriber, typically in a clinical setting such as a hospital or infusion centre. The infusion rate and duration depend on the indication and patient-specific factors.

Serious risks include hepatotoxicity (significant liver injury), severe hypersensitivity reactions such as anaphylaxis, infusion‑related events like hypotension or bronchospasm, and rare cases of renal impairment. Patients should be monitored for signs of liver dysfunction, allergic reactions, and changes in renal function during treatment.

Mycamine is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled renal disease, or those receiving interacting medications that could increase toxicity. Clinical judgment should guide use in these populations.